Business Wire

ElectReon’s Electrified Roadways Named Among TIME’s 100 Best Inventions of 2021

10.11.2021 19:55:00 EET | Business Wire | Press release

Share

ElectReon (TASE: ELWS.TA), the leading provider of in-road wireless electric vehicle (EV) charging technology for commercial, public service, and passenger vehicles, today announced that its wireless EV charging technology has been named as one of TIME's 100 Best Inventions of 2021. The charging infrastructure, which can wirelessly charge EVs while in-motion and at-rest, was evaluated by TIME editors and correspondents around the world based on originality, creativity, effectiveness, ambition and impact.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110006071/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

TIME's Best Inventions of 2021 (Photo: Business Wire)

ElectReon has been at the forefront of implementing their technology on public roads in multiple countries, providing accessible and flexible charging options that can be customized to meet the needs of unique EV fleet operators in a wide range of urban mobility, transit and logistics services.

“We honored by the recognition of ElectReon’s wireless charging solution by TIME as we work to spread awareness on the viability of this technology in maximizing fleet owner vehicle efficiencies, eliminating the cost of fuel, and reducing their full lifecycle carbon emissions,” said Oren Ezer, CEO of ElectReon. “As we rapidly scale our deployments around the world, we envision this technology to play a key role in accelerating the mass transition towards total electrification and we look forward to continuing to build the transportation infrastructure of tomorrow with the ongoing outstanding support from our industry and governmental partners we have experienced until now.”

“In addition to this great honor, it is clear that national governments are waking up to the significant value of in-road wireless charging and Electric Road Systems (ERS) and demonstrating their support,” said Ezer. National governments in European countries such as Sweden, Germany, Italy and France are announcing their plans to incorporate thousands of miles of ERS in their transportation strategies over the next decade to achieve net-zero carbon emissions. The French government, for example, just launched a call for automated road mobility, connected service infrastructures that enable low-carbon transport proposal projects, such as Electric Road demonstrators, among others. The Swedish Transport Authority just released a tender for 26 miles (42 km) of commercial ERS between the cities of Örebro and Hallsberg, as the country’s second phase of its ongoing national ERS deployment scaling, and several states in the US, including Michigan, are releasing a Request for Proposals (RFP) specifically for in-road dynamic wireless charging technology.

As one of the first and only companies able to demonstrate in-motion wireless charging on public roads, the company is currently working on various pre-commercial projects across the globe ranging from Germany, Italy, Sweden and Israel with plans of expansion into North America. Most recently, ElectReon announced the development of its wireless charging network to support 200 public buses in Tel Aviv in the company’s first fully commercial deal with one of Israel’s largest Public Transport Operators, Dan Bus Company. ElectReon also announced the recent addition of former President of Israel, Reuven “Ruvi” Rivlin, as the company’s president to facilitate relationships with world leaders to increase EV adoption, reduce fleet emissions, and accelerate ElectReon’s global impact.

To view the full TIME 2021 Best Inventions list visit: the TIME website.

About ElectReon

ElectReon is the leading provider of wireless charging solutions for electric vehicles (EVs), providing end-to-end charging infrastructure and services to meet the needs and efficiency demands of shared, public and commercial fleet operators and consumers. The company’s proprietary inductive technology dynamically (while in motion) and statically (while stopped) charges EVs quickly and safely, eliminating range anxiety, lowering total costs of EV ownership, and reducing battery capacity needs—making it one of the most environmentally sustainable, scalable, and compelling charging solutions available today. ElectReon works with cities and fleet operators on a charging as a service (CaaS) platform that enables cost-effective electrification of public, commercial, and autonomous fleets for smooth and continuous operation. For more information, visit electreon.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

MEDIA
Janine Ward on behalf of ElectReon
ElectReon@antennagroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye